PHARMACOKINETICS AND METABOLISM OF ANTIEPILEPTIC DRUGS IN ELDERLY PATIENTS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。我们的目标是研究高龄对抗癫痫药物药代动力学和代谢的影响。选定的老年和成年男性和女性使用苯妥英钠(PHT或CBZ)作为癫痫的单一疗法将进行评估。患者将接受部分口服PHT，作为稳定标记的PHT，在5分钟内静脉注射100毫克(仅一次)。稳定标记的PHT没有放射性，表现出与未标记的PHT相同的动力学和代谢。将对血液样本和尿液采集进行分析。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our goal is to investigate the effect of advanced age on antiepileptic drug pharmacokinetics and metabolism. Selected elderly and adult male and female ambulant patients taking phenytoin (PHT or CBZ) as monotherapy for epilepsy will be evaluated. The patients will receive a portion of their oral dose of PHT as stable-labeled PHT given intravenously as 100 mg over 5 minutes (one time only). Stable-labeled PHT is NOT radioactive and exhibits the same kinetics and metabolism as unlabeled PHT. Blood samples and urine collections will be analyzed.